Dr Andy Moore
Dr

Andy Moore

Email: 

Background

Associate Professor Andy Moore is a Paediatric Oncologist and Director of Research at Children's Health Queensland Hospital & Health Service (CHQ). He is also Director of the Queensland Children's Tumour Bank, a unique resource located on the Queensland Children's Hospital precinct, facilitating local, national and international collaborative research across all childhood cancer types and supporting enrolment of children on clinical trials. A/Prof. Moore's clinical and research interests focus on childhood leukaemia, particularly acute myeloid leukaemia (AML), an aggressive form of leukaemia with a poor prognosis. He also holds a number of leadership and advisory roles, including Deputy Chair of the Australian & New Zealand Childrens Haematology / Oncology Group (ANZCHOG).

Availability

Dr Andy Moore is:
Not available for supervision
Media expert

Fields of research

Biomedical and Clinical Sciences Cancer genetics Cancer therapy (excl. chemotherapy and radiation therapy) Cardiovascular medicine and haematology Chemotherapy Haematological tumours Haematology Molecular targets Oncology and carcinogenesis Oncology and carcinogenesis not elsewhere classified Paediatrics Solid tumours

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, The University of Queensland
  • Doctor of Philosophy, University College London

Research interests

  • Acute Myeloid Leukaemia

  • Leukaemia

  • Blood Cancers

  • Paediatric Oncology

  • Childhood Cancer

  • Biobanking

Search Professor Andy Moore’s works on UQ eSpace

96 works between 2007 and 2024
All (96) Journal Article (79) Conference Publication (17)

81 - 96 of 96 works

2012

Journal Article

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

Bavetsias, Vassilios, Crumpler, Simon, Sun, Chongbo, Avery, Sian, Atrash, Butrus, Faisal, Amir, Moore, Andrew S., Kosmopoulou, Magda, Brown, Nathan, Sheldrake, Peter W., Bush, Katherine, Henley, Alan, Box, Gary, Valenti, Melanie, Brandon, Alexis de Haven, Raynaud, Florence I., Workman, Paul, Eccles, Suzanne A., Bayliss, Richard, Linardopoulos, Spiros and Blagg, Julian (2012). Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 55 (20), 8721-8734. doi: 10.1021/jm300952s

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia

2012

Journal Article

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns

Moore, A. S., Faisal, A., Gonzalez de Castro, D., Bavetsias, V., Sun, C., Atrash, B., Valenti, M., de Haven Brandon, A., Avery, S., Mair, D., Mirabella, F., Swansbury, J., Pearson, A. D. J., Workman, P., Blagg, J., Raynaud, F. I., Eccles, S. A. and Linardopoulos, S. (2012). Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns. Leukemia, 26 (7), 1462-1470. doi: 10.1038/leu.2012.52

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: A model for emerging clinical resistance patterns

2012

Journal Article

A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay

Norris, R. L. G., Paul, M., George, R., Moore, A., Pinkerton, R., Haywood, A. and Charles, B. (2012). A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay. Journal of Chromatography B, 898, 136-140. doi: 10.1016/j.jchromb.2012.04.003

A stable-isotope HPLC-MS/MS method to simplify storage of human whole blood samples for glutathione assay

2011

Journal Article

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach

Moore, Andrew S., Norris, Ross, Price, Gareth, Nguyen, Thu, Ming, Ni, George, Rani, van Breda, Karin, Duley, John, Charles, Bruce and Pinkerton, Ross (2011). Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach. Journal of Paediatric and Child Health, 47 (12), 875-882. doi: 10.1111/j.1440-1754.2011.02103.x

Vincristine pharmacodynamics and pharmacogenetics in children with cancer: A limited-sampling, population modelling approach

2011

Journal Article

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia

Podesta, Jennifer E., Sugar, Richard, Squires, Matt, Linardopoulos, Spiros, Pearson, Andrew D. J. and Moore, Andrew S. (2011). Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. Leukemia Research, 35 (9), 1273-1275. doi: 10.1016/j.leukres.2011.05.022

Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia

2011

Conference Publication

Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients

Lobb, M., Norris, R. L. G., Charles, B., Gilshenan, K., Moore, A. and Pinkerton, R. (2011). Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients. 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Stuttgart, Germany, 2-6 October, 2011. Philadelphia PA, United States: Lippincott Wiliams & Wilkins. doi: 10.1097/01.ftd.0000400651.94145.ba

Blood collection technique for pharmacokinetic studies of doxorubicin in paediatric patients

2011

Conference Publication

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736

Moore, AS, Faisal, A, Bavetsias, V, de Castro, DG, Sun, CB, Atrash, B, Valenti, M, Brandon, AD, Avery, S, Pearson, ADJ, Workman, P, Blagg, J, Raynaud, FI, Eccles, SA and Linardopoulos, S (2011). Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736. 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), San Diego CA, DEC 10-13, 2011.

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736

2010

Journal Article

Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

Moore, A. S., Blagg, J., Linardopoulos, S. and Pearson, A. D. J. (2010). Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia, 24 (4), 671-678. doi: 10.1038/leu.2010.15

Aurora kinase inhibitors: Novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

2010

Conference Publication

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.

Podesta, JE, Griffin, MJ, Sugar, R, Squires, MS, Boddy, A, Linardopoulos, S, Pearson, ADJ and Moore, AS (2010). Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando FL, DEC 04-07, 2010.

Adaptation and Validation of the Plasma Inhibitory Activity (PIA) Assay to Detect Inhibition of Aurora, ABL and FLT3 kinases by AT9283 In Children and Adolescents with Leukaemia.

2010

Conference Publication

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

Moore, AS, Faisal, A, Bavetsias, V, Sun, CB, Atrash, B, Valenti, M, Brandon, AD, Avery, S, Raynaud, FI, Workman, P, Pearson, ADJ, Blagg, J, Eccles, SA and Linardopoulos, S (2010). Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo. 52nd Annual Meeting of the American-Society-of-Hematology (ASH), Orlando FL, DEC 04-07, 2010.

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

2009

Journal Article

Vincristine: Can its therapeutic index be enhanced?

Moore, Andrew and Pinkerton, Ross (2009). Vincristine: Can its therapeutic index be enhanced?. Pediatric Blood and Cancer, 53 (7), 1180-1187. doi: 10.1002/pbc.22161

Vincristine: Can its therapeutic index be enhanced?

2009

Journal Article

Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva

Moore, Andrew S., Wilson, Peter G., McKelvie, Penny, La Nauze, Jamie and Hirst, Lawrence W. (2009). Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva. Pediatric Blood and Cancer, 53 (4), 669-671. doi: 10.1002/pbc.22062

Localised peripheral primitive neuroectodermal tumour (PNET) of the conjunctiva

2009

Journal Article

Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

Moore, A.S., Shaw, P.J., Hallahan, A.R., Carter, T, Kilo, T, Nivison-Smith, I, O'Brien, T.A., Tapp, H, Teague, L, Wilson, S.R. and Tiedemann, K (2009). Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group. Medical Journal of Australia, 190 (3), 121-125.

Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children's Haematology Oncology Group

2008

Conference Publication

Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience

Moore, A.S. and Hallahan, A.R. (2008). Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience. 48th Annual Scientific Meeting of the British Society for Haematology, Glasgow, Scotland, 7-9 April 2008. United Kingdom: Wiley-Blackwell Publishing Ltd.. doi: 10.1111/j.1365-2141.2008.07061.x

Use of etanercept in children following haematopoietic stem cell transplantation: a single institution experience

2007

Journal Article

Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids

Moore, A, Suppiah, R and Weier, S (2007). Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids. Journal of Paediatrics And Child Health, 43 (5), 415-416. doi: 10.1111/j.1440-1754.2007.01094.x

Re: Hyponatraemia and seizures in oncology patients associated with hypotonic intravenous fluids

2007

Conference Publication

Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?

Moore, Andrew, Charles, Bruce, Wilkinson, Catherine, Weier, Steven and Pinkerton, Ross (2007). Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?. 39th Annual Conference of the International Society of Paediatric Oncology SIOP 2007, Mumbai, India, 31 October-3 November 2007. Hoboken: Wiley-Liss, Inc. doi: 10.1002/pbc.21342

Does myelosuppression during consolidation or high-dose methotrexate clearance correlate with tolerance of initial maintenance therapy in childhood acute lymphoblastic leukaemia?

Current funding

  • 2023 - 2026
    Life and health after childhood cancer: a national data linkage cohort study (Cancer Australia grant led by The University of Sydney)
    University of Sydney
    Open grant
  • 2021 - 2026
    Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of innovative catheter lock solutions
    Cancer Council Queensland
    Open grant

Past funding

  • 2021 - 2024
    The Queensland Children's Tumour Bank
    The Children's Hospital Foundation
    Open grant
  • 2020 - 2021
    Biobank Network
    Australian and New Zealand Children's Haematology/Oncology Group
    Open grant
  • 2020 - 2022
    PiggyBac transposon UCB-CAR19-NK cells: a novel off-the-shelf cellular immunotherapy for children with CD19+ blood cancers
    Children's Hospital Foundation Immunotherapy Research Grants
    Open grant
  • 2019 - 2021
    New strategies for targeting immune evasion in children's brain tumours
    The Children's Hospital Foundation
    Open grant
  • 2017 - 2020
    Circular RNAs as Trojan Horses of Oncogenesis (RSNCRT grant led by Flinders University)
    Flinders University
    Open grant
  • 2017 - 2019
    Zero Childhood Cancer
    Childrens Cancer Institute Australia
    Open grant
  • 2017 - 2022
    BDHP - Maternal and Child Health Theme
    Brisbane Diamantina Health Partners - Metro South
    Open grant
  • 2017 - 2018
    Developing novel immunotherapies for childhood blood cancers using advanced, humanised mouse models.
    The Kid's Cancer Project
    Open grant
  • 2017
    Improving the detection of residual disease in childhood acute myeloid leukaemia
    The Children's Hospital Foundation
    Open grant
  • 2016 - 2018
    Developing novel immunotherapies for childhood acute myeloid leukaemia using advanced, humanised mouse models
    The Children's Hospital Foundation
    Open grant
  • 2016 - 2019
    Personalised disease monitoring for improved outcomes in childhood acute myeloid leukaemia
    The Kid's Cancer Project
    Open grant
  • 2016 - 2017
    Personalised disease monitoring to improve treatment of childhood acute myeloid leukaemia
    The Children's Hospital Foundation
    Open grant
  • 2015 - 2016
    Identification of residual disease and novel therapeutic targets in acute myeloid leukaemia (AML)
    The Kid's Cancer Project
    Open grant
  • 2015 - 2016
    Advancing childhood brain tumour research through the Queensland Children's Tumour Bank
    Brainchild Foundation
    Open grant
  • 2015 - 2016
    The impact of re-induction chemotherapy and minimal residual disease on allogeneic haematopoietic stem cell transplantation outcomes for children with acute myeloid leukaemia in second remission.
    Australian and New Zealand Children's Haematology/Oncology Group
    Open grant
  • 2014
    The preclinical development of CBL137 in paediatric AML
    Cancer Bequest Fund
    Open grant
  • 2014 - 2016
    Cell-cycle checkpoint signalling as a novel therapeutic target in paediatric acute myeloid leukaemia (AML)
    Oncology Children's Foundation
    Open grant
  • 2014 - 2017
    The Watts Trust Estate funds for paediatric leukaemia research
    Children's Health Queensland Hospital and Health Service - Oncology Service Group
    Open grant
  • 2014
    Identification of novel therapeutic strategies for childhood acute myeloid leukaemia through integrated genomic and phospho-proteomic analyses
    UQ Early Career Researcher
    Open grant
  • 2014
    Optimising the utility of paediatric research samples using advanced liquid handling and dispensing equipment
    NHMRC Equipment Grant
    Open grant
  • 2013 - 2014
    The Kid's Cancer Project
    Research Donation Generic
    Open grant
  • 2013 - 2018
    The Queensland Children's Tumour Bank - Helping Develop Better Approaches for Treating Childhood Cancers
    Research Donation Generic
    Open grant
  • 2013 - 2014
    Maximising the use of donated tumour tissue from Queensland children for research aimed at improving the diagnosis and treatment of paediatric brain tumours
    Brainchild Foundation
    Open grant
  • 2013 - 2016
    The evaluation of MEK inhibition as a therapeutic strategy for childhood acute myeloid leukaemia
    Children's Health Foundation Queensland
    Open grant
  • 2013 - 2014
    Aminopeptidase inhibition as a therapeutic strategy for childhood acute myeloid leukaemia (I L Thompson Research Fellowship)
    IL Thompson Research Fellowship
    Open grant
  • 2012 - 2013
    The preclinical development of Tosedostat for the treatment of childhood acute myeloid leukaemia
    UQ New Staff Research Start-Up Fund
    Open grant
  • 2012 - 2014
    The role Survivin and XIAP (X-linked inhibitor of apoptosis protein) as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia
    Pfizer Australia Pty Limited
    Open grant
  • 2012 - 2016
    A study to assess the mechanisms of cell death in acute myeloid leukaemia
    Children's Health Foundation Queensland
    Open grant
  • 2012 - 2016
    NHMRC Early Career Fellowship (Australian Health Professional): The role Survivin and XIAP as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia
    NHMRC Training (Postdoctoral) Fellowship
    Open grant
  • 2012 - 2013
    The role Survivin and XIAP (X-linked inhibitor of apoptosis protein) as biomarkers and therapeutic targets in paediatric acute myeloid leukaemia
    ANZ Executors and Trustees' Company Ltd
    Open grant
  • 2007 - 2021
    Queensland Children's Tumour Bank
    Royal Children's Hospital Foundation
    Open grant

Availability

Dr Andy Moore is:
Not available for supervision

Supervision history

Completed supervision

Enquiries

Contact Dr Andy Moore directly for media enquiries about:

  • Childhood Cancer
  • Childhood Leukaemia

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au